← Research library

Ganapolsky climate chambers: Cortexin, Noopept and related comparators

Comparison in people · 2008

What was studied
301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Main finding
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.

Cortexin · cold (n=17) · 155 → 210 W vs 159 → 162 W with placebo · Before chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls.

Related evidence maps: Military & occupational ↗

Reported findings and study design

In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.

Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.

Population or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.

Dose, route and schedule

Intranasal amounts in the author abstract: Cortexin 0.5 mg, Noopept 0.1 mg, Cerebrolysin 43 mg, Dilept 0.1 mg, Semax 0.2 mg and Deltaran 20 mg. Oral Vinpotropil contained piracetam 400 mg and vinpocetine 5 mg. Arms and testing series differ.

Protocol source ↗ · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.

Results · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
MeasureResultComparison, timing and statistics
Cortexin · cold (n=17)155 → 210 W vs 159 → 162 W with placeboBefore chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls.
Noopept · heat (n=18)182 → 188 W vs 164 → 152 W with placeboBefore chamber to during exposure; the 188 W mean is marked p<0.05 versus placebo.
Cortexin · simulated altitude170 → 170 W vs 162 → 154 W with placebo
Cerebrolysin · heat (n=17)194 → 138 W vs 164 → 152 W with placebo
Dilept · cold (n=16)182 W during exposureThe author reports 12% higher than the historical untreated control.
Semax · cold (n=17)195 → 161 WSeparate comparison. The in-chamber group mean was near control.
Deltaran · cold (n=18)196 → 217 WSeparate comparison. The author reports a significant increase from the pre-chamber measure.
Selected in-chamber PWC₁₇₀ means (W)
Selected in-chamber PWC₁₇₀ means (W)
GroupColdHeatSimulated altitude
Cortexin (n=17)210155170
Noopept (n=18)189188197
Cerebrolysin (n=17)157138152
Placebo (n=9)162152154

PWC₁₇₀ is the cycling workload at 170 beats/min. These are descriptive group means.

The ledger uses the 301-person dissertation total once for these related reports.

Source for these results ↗ · Reviewed 2026-11-17

Study limitations and source details

Study limitations

  • Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation.
  • Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.

Related publications may describe some of the same participants or experiments.

Source details

Original dissertation author abstract · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.

Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.

Reported methods, results and evidence limitations

Sources checked

Added to the library

Citation

Human comparative studyRussian-language source

V. P. Ganapolsky. Ganapolsky climate chambers: Cortexin, Noopept and related comparators Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards